-
Mashup Score: 5
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® | Biogen - 26 day(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4News | Biogen - 28 day(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1STATUS List - Chris Viehbacher - 3 month(s) ago
Chris Viehbacher is managing biotech’s highest-profile turnaround act, shuffling leadership, refreshing the Biogen board, and cutting company spending.
Source: www.statnews.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 43Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
We’ve received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for our treatment for amyotrophic lateral sclerosis (#ALS) in adults who have a specific gene mutation. Learn more about this news: https://t.co/BMl83MOB1e https://t.co/U2enSmz3Nb
-
-
Mashup Score: 1Events | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Biogen Fourth Quarter and Full Year 2023 Earnings Call - 1651786 - 3 month(s) ago
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first…
Source: event.webcasts.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3News | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
Along with @EisaiUS, we’ve initiated the rolling submission of a Biologics License Application to the U.S. #FDA for the investigational subcutaneous formulation of our drug for early #AlzheimersDisease. Learn more about this #news: https://t.co/h3TU79jrzP https://t.co/UgXPQEUhRd